Amedisys Target of Unusually High Options Trading (AMED)

Amedisys Inc (NASDAQ:AMED) was the recipient of some unusual options trading on Thursday. Investors acquired 1,441 call options on the company. This represents an increase of 1,142% compared to the average volume of 116 call options.

Amedisys (NASDAQ:AMED) opened at $50.68 on Tuesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.33 and a quick ratio of 1.33. The company has a market capitalization of $1,745.03, a price-to-earnings ratio of 40.54, a price-to-earnings-growth ratio of 1.07 and a beta of 0.73. Amedisys has a one year low of $45.18 and a one year high of $65.91.

A number of institutional investors have recently bought and sold shares of AMED. Point72 Asset Management L.P. boosted its stake in Amedisys by 337.0% in the third quarter. Point72 Asset Management L.P. now owns 474,044 shares of the health services provider’s stock worth $26,528,000 after purchasing an additional 674,044 shares in the last quarter. American Century Companies Inc. boosted its stake in Amedisys by 41.4% in the third quarter. American Century Companies Inc. now owns 1,671,680 shares of the health services provider’s stock worth $93,547,000 after purchasing an additional 489,220 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Amedisys by 29.7% in the third quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock worth $83,048,000 after purchasing an additional 339,825 shares in the last quarter. Balyasny Asset Management LLC acquired a new position in Amedisys in the second quarter worth $7,736,000. Finally, Bank of New York Mellon Corp boosted its stake in Amedisys by 10.8% in the third quarter. Bank of New York Mellon Corp now owns 846,575 shares of the health services provider’s stock worth $47,375,000 after purchasing an additional 82,247 shares in the last quarter. 94.97% of the stock is currently owned by institutional investors.

A number of brokerages have weighed in on AMED. Zacks Investment Research cut Amedisys from a “buy” rating to a “hold” rating in a research report on Friday. Mizuho reiterated a “buy” rating and issued a $65.00 price target (up from $55.00) on shares of Amedisys in a research report on Wednesday, November 8th. Benchmark reiterated a “hold” rating on shares of Amedisys in a research report on Thursday, November 9th. Craig Hallum reiterated a “buy” rating and issued a $68.00 price target (up from $55.00) on shares of Amedisys in a research report on Thursday, November 9th. Finally, BidaskClub cut Amedisys from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $61.09.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.com-unik.info/2018/02/06/amedisys-target-of-unusually-high-options-trading-amed.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit